160 related articles for article (PubMed ID: 17041100)
1. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Abi-Habib RJ; Singh R; Liu S; Bugge TH; Leppla SH; Frankel AE
Mol Cancer Ther; 2006 Oct; 5(10):2556-62. PubMed ID: 17041100
[TBL] [Abstract][Full Text] [Related]
2. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
3. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Su Y; Ortiz J; Liu S; Bugge TH; Singh R; Leppla SH; Frankel AE
Cancer Res; 2007 Apr; 67(7):3329-36. PubMed ID: 17409442
[TBL] [Abstract][Full Text] [Related]
4. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Liu S; Bugge TH; Leppla SH
J Biol Chem; 2001 May; 276(21):17976-84. PubMed ID: 11278833
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of a urokinase activation-dependent anthrax toxin.
Rønø B; Rømer J; Liu S; Bugge TH; Leppla SH; Kristjansen PE
Mol Cancer Ther; 2006 Jan; 5(1):89-96. PubMed ID: 16432166
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Liu S; Bugge TH; Frankel AE; Leppla SH
Methods Mol Biol; 2009; 539():175-90. PubMed ID: 19377974
[TBL] [Abstract][Full Text] [Related]
7. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts.
Abi-Habib RJ; Liu S; Bugge TH; Leppla SH; Frankel AE
Blood; 2004 Oct; 104(7):2143-8. PubMed ID: 15161668
[TBL] [Abstract][Full Text] [Related]
8. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
[TBL] [Abstract][Full Text] [Related]
9. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
10. Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Bekdash A; Darwish M; Timsah Z; Kassab E; Ghanem H; Najjar V; Ghosn M; Nasser S; El-Hajj H; Bazerbachi A; Liu S; Leppla SH; Frankel AE; Abi-Habib RJ
Transl Oncol; 2015 Oct; 8(5):347-357. PubMed ID: 26500025
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Nishiya AT; Nagamine MK; Fonseca IIMD; Miraldo AC; Scattone NV; Guerra JL; Xavier JG; Santos M; Gomes COMS; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32121654
[TBL] [Abstract][Full Text] [Related]
13. Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
Martin EW; Buzza MS; Driesbaugh KH; Liu S; Fortenberry YM; Leppla SH; Antalis TM
Oncotarget; 2015 Oct; 6(32):33534-53. PubMed ID: 26392335
[TBL] [Abstract][Full Text] [Related]
14. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
16. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Borgfeldt C; Hansson SR; Gustavsson B; Måsbäck A; Casslén B
Int J Cancer; 2001 May; 92(4):497-502. PubMed ID: 11304683
[TBL] [Abstract][Full Text] [Related]
17. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
20. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
